Research programme: Dual-Affinity Re-Targeting antiviral therapeutics - MacroGenicsAlternative Names: MGD 014
Latest Information Update: 28 Oct 2015
At a glance
- Originator MacroGenics
- Class Bispecific antibodies; Proteins
- Mechanism of Action CD3 antigen inhibitors; Viral RNA inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical HIV infections
Most Recent Events
- 14 Oct 2015 Preclinical trials in HIV infections in USA (Parenteral)